Phosphorylation of RIPK1 at S166, a marker of activation, is significantly increased in AD patient brains and AlCl3-induced AD rat models, alongside elevated RIPK3, phosphorylated MLKL, and CYLD levels, and decreased cIAP1 and cIAP2 expression. This evidence concerns the gene CYLD and Alzheimer disease.